End-of-day quote
INDONESIA S.E.
06:00:00 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
1,420
IDR
|
-1.73%
|
|
-2.41%
|
-11.80%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
75,937,698
|
69,371,962
|
75,699,810
|
96,674,291
|
74,471,583
|
66,839,402
|
-
|
-
|
Enterprise Value (EV)
2 |
73,518
|
65,231
|
69,972
|
93,892
|
74,472
|
62,946
|
61,730
|
60,562
|
P/E ratio
|
30.3
x
|
25.4
x
|
24.6
x
|
28.7
x
|
26.9
x
|
20.8
x
|
18.9
x
|
16.4
x
|
Yield
|
1.6%
|
1.76%
|
1.73%
|
-
|
-
|
2.3%
|
2.34%
|
2.95%
|
Capitalization / Revenue
|
3.35
x
|
3
x
|
2.88
x
|
3.34
x
|
2.45
x
|
2.05
x
|
1.91
x
|
1.78
x
|
EV / Revenue
|
3.25
x
|
2.82
x
|
2.67
x
|
3.25
x
|
2.45
x
|
1.93
x
|
1.76
x
|
1.61
x
|
EV / EBITDA
|
19.5
x
|
15.8
x
|
15
x
|
19
x
|
17.1
x
|
12.8
x
|
11.5
x
|
10.2
x
|
EV / FCF
|
95.5
x
|
19.8
x
|
30.1
x
|
166
x
|
-
|
20.1
x
|
28.9
x
|
29.1
x
|
FCF Yield
|
1.05%
|
5.05%
|
3.32%
|
0.6%
|
-
|
4.98%
|
3.46%
|
3.43%
|
Price to Book
|
4.78
x
|
3.99
x
|
3.87
x
|
4.74
x
|
-
|
2.91
x
|
2.68
x
|
2.48
x
|
Nbr of stocks (in thousands)
|
46,875,122
|
46,872,947
|
46,872,947
|
46,255,641
|
46,255,641
|
46,255,641
|
-
|
-
|
Reference price
3 |
1,620
|
1,480
|
1,615
|
2,090
|
1,610
|
1,445
|
1,445
|
1,445
|
Announcement Date
|
2/27/20
|
4/7/21
|
2/22/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
1IDR in Million2IDR in Billions3IDR Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22,636
|
23,113
|
26,255
|
28,934
|
30,449
|
32,608
|
35,024
|
37,529
|
EBITDA
1 |
3,771
|
4,137
|
4,649
|
4,946
|
4,360
|
4,917
|
5,354
|
5,923
|
EBIT
1 |
3,300
|
3,555
|
4,021
|
4,231
|
3,694
|
4,179
|
4,579
|
5,173
|
Operating Margin
|
14.58%
|
15.38%
|
15.32%
|
14.62%
|
12.13%
|
12.82%
|
13.07%
|
13.78%
|
Earnings before Tax (EBT)
1 |
3,348
|
3,628
|
4,073
|
4,459
|
3,606
|
4,265
|
4,629
|
5,257
|
Net income
1 |
2,499
|
2,733
|
3,074
|
3,382
|
2,767
|
3,232
|
3,543
|
4,044
|
Net margin
|
11.04%
|
11.83%
|
11.71%
|
11.69%
|
9.09%
|
9.91%
|
10.12%
|
10.78%
|
EPS
2 |
53.48
|
58.31
|
65.60
|
72.71
|
59.81
|
69.57
|
76.34
|
87.91
|
Free Cash Flow
3 |
769,646
|
3,294,552
|
2,322,036
|
566,431
|
-
|
3,132,000
|
2,136,000
|
2,079,500
|
FCF margin
|
3,400.1%
|
14,254.32%
|
8,844.17%
|
1,957.7%
|
-
|
9,605.07%
|
6,098.7%
|
5,541.04%
|
FCF Conversion (EBITDA)
|
20,412.02%
|
79,640.87%
|
49,942.71%
|
11,452.5%
|
-
|
63,690.98%
|
39,897.74%
|
35,108.41%
|
FCF Conversion (Net income)
|
30,798.15%
|
120,535.64%
|
75,537.95%
|
16,747.36%
|
-
|
96,895.3%
|
60,283.17%
|
51,419.65%
|
Dividend per Share
2 |
26.00
|
26.00
|
28.00
|
-
|
-
|
33.23
|
33.86
|
42.66
|
Announcement Date
|
2/27/20
|
4/7/21
|
2/22/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
1IDR in Billions2IDR3IDR in Million Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
7,310
|
-
|
7,888
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
1,051
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
877.6
|
-
|
979
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
12.01%
|
-
|
12.41%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
843.4
|
-
|
955.2
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
786.3
|
-
|
802.1
|
848.6
|
896.7
|
855.7
|
673.3
|
535.9
|
701.8
|
803
|
590.6
|
808.5
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
9.21%
|
-
|
8.9%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
16.79
|
-
|
17.26
|
18.32
|
19.28
|
18.40
|
14.47
|
11.52
|
15.42
|
17.13
|
12.60
|
17.25
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
35.00
|
-
|
-
|
-
|
38.00
|
-
|
-
|
29.51
|
-
|
-
|
-
|
34.00
|
Announcement Date
|
2/22/22
|
4/28/22
|
7/29/22
|
10/31/22
|
3/28/23
|
4/28/23
|
8/7/23
|
10/31/23
|
4/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,419
|
4,141
|
5,728
|
2,782
|
-
|
3,894
|
5,110
|
6,278
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
769,646
|
3,294,552
|
2,322,036
|
566,431
|
-
|
3,132,000
|
2,136,000
|
2,079,500
|
ROE (net income / shareholders' equity)
|
16.4%
|
16.4%
|
17.2%
|
16.9%
|
-
|
14%
|
14.2%
|
14.7%
|
ROA (Net income/ Total Assets)
|
13.1%
|
12.8%
|
13.2%
|
12.8%
|
-
|
11.1%
|
11.1%
|
11.7%
|
Assets
1 |
19,146
|
21,414
|
23,288
|
26,454
|
-
|
28,562
|
31,070
|
33,239
|
Book Value Per Share
3 |
339.0
|
371.0
|
418.0
|
441.0
|
-
|
495.0
|
538.0
|
579.0
|
Cash Flow per Share
3 |
53.40
|
90.10
|
60.30
|
27.30
|
-
|
102.0
|
89.70
|
94.00
|
Capex
1 |
1,733
|
927
|
457
|
705
|
-
|
1,108
|
984
|
937
|
Capex / Sales
|
7.66%
|
4.01%
|
1.74%
|
2.44%
|
-
|
3.4%
|
2.82%
|
2.5%
|
Announcement Date
|
2/27/20
|
4/7/21
|
2/22/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
1IDR in Billions2IDR in Million3IDR Last Close Price
1,445
IDR Average target price
1,758
IDR Spread / Average Target +21.66% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.25% | 4.16B | | +33.43% | 700B | | +27.63% | 569B | | -5.12% | 358B | | +19.59% | 330B | | +4.89% | 287B | | +16.58% | 236B | | +6.79% | 202B | | -9.08% | 197B | | +4.26% | 161B |
Other Pharmaceuticals
|